REGMEDXB
FROM CARE TO CURE

Annual Report 2024








Index



Foreword

Dear reader,

The Annual Report 2024 marks another important chapter in the evolution of RegMed XB, continuing to build on the strong foundations laid in previous years as a translational platform.

This year, RegMed XB has witnessed the first tangible results of the Moonshot roadmaps come to life—transforming bold vision into measurable progress in both the Netherlands and Flanders. The RegMed XB Pilot Factory is transitioning from blueprint to reality, setting a new benchmark for scalable regenerative medicine production. As the ecosystem internationally grows, so too does the momentum behind the mission: delivering regenerative medicine solutions while establishing a competitive and sustainable industry.

Securing long-term funding remains a top priority. In 2024, RegMed XB successfully applied for the new Health~Holland funding and was awarded €6 million. The Thematic Technology Transfer program (2019–2024) was successfully completed, and RegMed XB has jointly applied with the DCVA for its successor program.

All of this is possible thanks to the trust and commitment of partners—academic, industrial, health foundations, and all levels of government. Their continued support drives this shared progress.

Let's continue to innovate, collaborate, and accelerate—because together, we make the impossible possible.

Bernard Mulder

General Director RegMed XB

Objectives and activities

RegMed XB aims to deliver regenerative medicine (RM) solutions to patients at an affordable cost while fostering a new industrial sector in the Netherlands and Flanders.

The initiative is mobilizing funds and resources to achieve these objectives, as well as establishing a much-needed network at both national and international levels alongside like-minded initiatives. This will enable RegMed XB to continue growing into a sizable, internationally leading translational research institute in the field of regenerative medicine.

Regional economic growth
RegMed XB contributes -and will continue to contribute- to regional economic growth by generating jobs, fostering new businesses, and supporting existing companies.

The organisation firmly believes that these economic goals can be successfully combined with improved affordability and accessibility of regenerative medicine solutions for patients, as well as accelerating research and development toward practical applications.

Pilot Factory
With RegMed XB's Pilot Factory, thanks to the grant of the National Growth Fund, access to manufacturing infrastructure for the production of RM solutions has become available in the coming years, helping to achieve the goals of RegMed XB: bringing RM solutions to patients at affordable cost and creating a new industrial sector in the participating regions.

Statutory aims of Foundation RegMed XB

- **combine resources of academic partners, business, provinces and health foundations, due to which researchers and entrepreneurs can perform fundamental, applied and translational research on regenerative medicine and as a result will contribute to affordable healthcare;**
- **provide services regarding project and programme management, including support, control and reporting;**
- **carrying out any further activities, which may be beneficial to all mentioned above, in the broadest sense;**
- **the Foundation explicitly does not seek to make profit and/or represent commercial interests.**

Governance model

The governance model of the foundation is as follows: The Management team consists of a Statutory General Director (GD), a Medical Scientific Director (MSD), a Director of Operations (DoO), a Finance Manager (FFM), a representative of RegMed XB Flanders (FL), and a Patient Advocate, reports to the Supervisory Board and is advised by the Scientific Advisory Board.

The Management team, consisting of Bernard Mulder (GD), Frank Luyten (MSD), Erik Eijrond (DoO), Olaf Geurts (FFM) and Bart Geers (FL), they have been responsible for the daily operational management during the year 2024. Tom Oostrom holds the position of Patient Advocate as non-executive member of the Board of Directors. The Board of Directors was supported by two Project Managers, two Impact Officers, a Legal Counsel, a Communications Manager and two Management Assistants.

In 2024, changes in the Supervisory Board took place as three members left the Board after years of contribution to RegMed XB, and the Board welcomed four new members.

Koenraad Debackere

Jopie Nooren (till Sept 2024)

Luc Keltjens (till Oct 2024)

Wim van der Meeren (till Nov 2024)

Maurice Horsten (as from Jun 2024)

Conny Helder (as from Sept 2024)

Arno van Son (as from Nov 2024)

Floris Italianer (as from Nov 2024)

Supervisory Board

Bernard Mulder
General Director

Frank Luyten
Medical Scientific Director

Erik Eijrond
Director of Operations

Olaf Geurts
Finance Manager

Bart Geers
Chair RegMed XB vzw (Flanders)

Management team

In addition to the foundation's governance
Efforts were made in 2024 to develop a new model for partner involvement in RegMed XB. Partners seek closer engagement in the organisation's developments. As part of this initiative, the 'Toezichtsvisie' was created, outlining two councils: the Partner Council and the Expert Council. The Partner Council consists exclusively of decision-makers from RegMed XB's partner organisations. Meanwhile, in 2025 the Expert Council will replace the Scientific Advisory Board, addressing the need for additional expertise in the development of regenerative medicine products.

Prof. dr. Katja Schenke-Layland
Eberhard Karls University

Prof. dr. Philippe Menasché
University of Paris Descartes

Prof. dr. René Bindels
Radboud Institute for Molecular Life Sciences

Prof. dr. Thierry Berney
University of Geneva

Prof. Dr. Alicia El Haj
University of Birmingham

Prof. Dr. Maurilio Sampaolesi
University of Leuven

Scientific Advisory Board

Quality control

RegMed XB's research is performed at the labs of the participating universities, university medical centers and within the participating companies using the local systems of quality control.

Within the RegMed XB project control cycle, the progress of the research program (called "Moonshots") is monitored on a bi-annual basis in the Moonshot leadership team meetings and reported to the Scientific Advisory Board.

- Three times a year, the Scientific Advisory Board monitors and evaluates progress made in the Moonshots.
- An International Scientific Advisory Board (ISAB) annually performs a peer review. The ISAB is organised per Moonshot and consists of members selected in close collaboration with the Health Foundations participating in the respective Moonshot.

The results of the peer reviews are discussed in a joint meeting of the Moonshot leaders and the Scientific Advisory Board and subsequently reported to the Health Foundations. The Scientific Advisory Board defines – based on ISAB outcomes – improvements within next years' programming.

Within the RegMed XB office, documentation of all major office processes has been drafted using standardised process protocols. These process protocols will continue to be improved in 2025.



Five Moonshots

Ambition and strategy

Ambition
Foundation RegMed XB aims to become an internationally leading translational research and valorization institute in the field of regenerative medicine focused on patients' needs with strong patient involvement to bring regenerative solutions to the market at affordable cost. Secondly, RegMed XB aims to establish a competitive and sustainable Regenerative Medicine industry in The Netherlands and Flanders.

Strategy
To achieve its ambition, RegMed XB comprises a collaboration of strong regional institutes and bundles their forces with top international research groups. RegMed XB brings together multiple Health Foundations, top scientists, entrepreneurs and governments to cooperatively integrate research and valorisation to shorten the time-to-patient and optimally translate research results into new businesses.



RegMed XB is based on five strategic activity pillars driving basic research towards solutions for patients

Funding

In July 2023, discussions with stakeholders regarding the funding of the office for the 2024-2026 period have been concluded in a manner that inspires confidence to realize our objectives and ambitions for the 2024-2026 period. Below an overview of other fundings.

Scale-up 2
The "Scale-up 2" project - an extension of the Phase 1 Diabetes-Moonshot. This project started in 2020 and the research has been completed at the end of 2024. The Final Report has been submitted to Health~Holland in June 2025.

Moonshots
- During 2024 follow-up projects within the Diabetes-, Cardiovascular- and Kidney- Moonshots have started, funded by the respective Health Foundations using both PPS allowances and their own resources.
- During 2024, in close collaboration with Flemish partners the "Cornea" project within the new eye Moonshot has also started.
- In 2024 RegMed XB also applied for further Moonshots funding from the new Health~Holland "PPS-innovatieregeling" and has been awarded €6 million for the coming years, starting from 2025. This will allow for continuation of the RegMed XB program.

Thematische Technology Transfer (TTT) grant
RegMed XB and the Dutch CardioVascular Alliance (DCVA) were granted a TTT-grant ("Thematische Technology Transfer") by the Ministry of Economic Affairs and Climate of in total €8 million for the period 2020-2024.
  - Part of these funds, €2,5 million, have been used for executing valorization activities, comprising of screening and scouting of potential business cases by impact officers in the regenerative medicine and cardiovascular fields, resulting in the creation of spin-offs. Other important valorization activities include setting up business education and a solid RM ecosystem by organising training programs and network events.
  - The other €5,5 million were used to set up the F1RST fund (Fonds InvesteringRijpe STarters (F1RST) Coöperatief U.A.) which is a pre-seed investment fund focusing on early seed funding of start-ups in the RM and cardiovascular fields. Both RegMed XB and DCVA committed to an investment of €2 million each, creating an investment fund of €9,5 million.

The fund is professionally managed by BGV (BioGeneration Ventures) in Naarden (NL). In general, the TTT-program has been considered so successful that the Ministry of Economic Affairs has initiated a follow-up program. RegMed XB and DCVA have applied for this new program and have received an invitation to present their plan "Impact Opschalen" to the TTT-selection committee in June 2025. In July 2025, RegMed XB and DCVA will learn whether a new grant will be awarded.

Pilot Factory
Following RegMed XB's September 2020 proposal to the National Growth Fund to build a national RegMed XB Pilot Factory for regenerative medicine, the Dutch Cabinet awarded this proposal with €56,3 million in 2021. During 2024, the Pilot Factory continued to build the infrastructure and capabilities and started to work on projects. Of the €56,3 million, €1,4 million awarded for the "penvoerder" tasks runs through the RegMed XB annual accounts.

Corporate social responsibility and environmental management

RegMed XB is aware of the social impact and ethical aspects of its activities and considers social responsibility therefore of paramount importance. RegMed XB is committed to a research approach in which animal testing is limited to legal and regulatory requirements.

Results 2024

The conclusion of the earlier research programs left the Moonshots with the need for a follow-up program. The RegMed XB Office initiated the discussions on the continuation of the Moonshots at the beginning of 2023 with the help of the Health Foundations. Based on insights gained from past years, Roadmaps were developed for all Moonshots, with short- and long-term goals.

1 Research-Excellence

A final Roadmap was set for the **Diabetes Moonshot** with the ultimate goal to make the Diabetes type I patient insulin independent. As a first step -Roadmap 1-, a device was developed to deliver islet transplants as a sentinel device. The International Scientific Advisory Board and the Scientific Advisory Board strongly supported this path forward. Funding was secured for the Roadmap 1, being the preclinical development and early clinical validation of this delivery device for beta-cells. Extensive testing including physical and chemical characterisation, cytotoxicity, sensitization, irritation and pyrogenicity was subcontracted to outside private partners to generate the quality of data required for the regulatory dossier. As for Roadmap 2, the development of a combination product being iPS derived beta cells delivered in the device, first steps were undertaken to transfer the stem cell differentiation protocols to a GMP compliant process, in collaboration with NecstGen. It is noteworthy to mention that the team developed a novel purification process leading to an enrichment of insulin secreting beta cells in the final cell preparation. These findings were part of new IP and published in a top tier journal.

For the **Osteoarthritis (OA) Moonshot**, a roadmap exercise is close to final with the ultimate goal to build a living joint as an alternative for the joint prosthetic devices, and this for the patient population less then 60 years old. The results of a business evaluation and the shorter-term OA valorization trajectory provided support for the development of a large osteochondral implant for the knee, “competing” in the existing allograft market in the USA. A proposal for a product development plan was presented to the Moonshot partners and is being further discussed. Further support for the OA Moonshot from WEWIS-Flanders was secured till 2026.

For the **Kidney and the Cardiovascular Moonshots,** long term roadmap discussions have not been finalized yet. Funding was obtained so that both Moonshots work on shorter term transition projects (2 years) supported by the relevant Foundations. For the Kidney Moonshot, an organ-on-a-chip screening platform is being developed with the industrial RegMed XB consortium partner Mimetas. For the Cardiovascular Moonshot, further exploration and validation of an ex vivo organ perfusion bioreactor system for the heart is ongoing.

For the **Eye Moonshot**, good progress was achieved with the obtained funding for the development of a combination product of a polymer membrane with shape memory characteristics (expertise Flanders) seeded with stem cell derived corneal endothelial cells (expertise Maastricht and Leiden). A Target Product Profile was defined and finalized with the help of an external consultant.

2 Business development & acceleration

With the closing of 2024, the TTT-program “Impact Versnellen” has come to an end. Here we provide an overview of the results accomplished in 2024 and of the overall program.

In 2024, Impact Officers working within this program identified 35 new promising academic projects through networking, screening scientific publications, and accessing project databases from hospitals and health foundations. In the same year, 15 vouchers have been granted, leading to a total of 42 since the start of the program.

Five additional startup companies which build on projects that have previously received a voucher were founded in 2024: JAMA Therapeutics, SBMatrices, XS Innovations, Myogene Therapeutics and Rouge Therapeutics. This brings the total amount of startups stemming from the TTT-program “Impact Versnellen” to 13.

3 Public-Private Entrepreneurship

Thanks to earlier lobbying, RegMed XB was able to secure €30 million in May 2024 for the new SRGO subsidy (“Subsidie Regeneratief Geneeskundig Onderzoek”), which is managed by the Netherlands Enterprise Agency (RVO).

This subsidy helps companies to accelerate development of their pipeline product by working closely together with academia. The company takes the initiative to submit a plan for this joint development.

4 Seed Capital

F1RST Fund Activities
The F1RST fund evaluated 44 new deal opportunities during 2024, of which 7 are still being pursued. 23% of the new opportunities were found through the voucher pipeline. The F1RST fund made investments in 3 newly founded companies in 2024: Rouge Therapeutics (€400k), XS Innovations (€350k) and STANT (€500k). Portfolio companies Phlox Therapeutics and Phosphoenix have successfully obtained follow-on investments. The F1RST Fund participated in both rounds with €250k and €300k respectively.

Investment Impact
F1RST has committed a total of €5,470,000 to investments. In addition, F1RST’s portfolio companies have raised €61,6 million in third-party funding, including €14 million in grants and €47 million in co-financing.

These results highlight the significant impact of our valorization and business development efforts in fostering innovation and accelerating the development of new healthcare solutions.

5 Infrastructure Pilot Factory

In 2024, the RegMed XB's Pilot Factory has taken further steps in the realisation of a national infrastructure for regenerative medicine (RG).

This infrastructure, consisting of development and production lines in Leiden (2x), Utrecht, Eindhoven and Maastricht, aims to accelerate the upscaling of innovative therapies.

More than three years after the start, organisational infrastructure is largely in order. In 2024, the intended results for user numbers and employment has been achieved. The two remaining production sites (ICAT and SBMC) will be completed in mid-2025, further increasing operational strength. The biggest challenge remains the lagging revenue development, partly caused by construction delays and slow market adoption. However, there are positive signs: the commercial partnership between NecstGen and Galapagos and a broader project portfolio point to growing market traction.

Progress per pilot line

NecstGen

NecstGen (Leiden): Realized an IPCEI grant in 2024, signed a contract with Galapagos for CAR-T production and welcomed the first cleanroom rental customer. Despite good market positioning, turnover development is lagging behind. Recruitment is difficult, so consultants are used for crucial positions.

LUMC Leids Universitair Medisch Centrum

LUMC – iPSC & OoC Hotel (Leiden): The center saw a sharp increase in requests for hiPSC lines and expanded its international collaborations, training programs and research. Activities contribute to standardisation and automation of organ-on-chip technology.

ICAT Innovation Center for Advanced Therapies

ICAT (Utrecht): Started the construction of a GMP facility within UMC Utrecht (completion mid-2025) and intensified cooperation with public-private parties. The contribution to education and clinical studies has grown.

SBMC Smart BioMaterials Consortium

SBMC (Eindhoven): Obtained the ISO 13485 certificate and implemented an electronic quality system. Construction of the pilot production facility has started (completion in mid-2025), but later then anticipated.

ReGEN Biomedical
Revolutionizing the production of functional tissues

ReGEN Biomedical (Maastricht): Technological development is accelerating, with successes in automation and participation in European HORIZON projects. Demcon joined as a technology partner and co-shareholder.

Joint activities

Joint activities between Pilot Lines (such as conferences, exchanges and HR cooperation) have been realised. Synergy in customer use between lines is still limited, partly due to the early phase of market development.

In conclusion, the RegMed XB's Pilot Factory is making solid progress in infrastructure, collaboration and innovation. The foundation for sustainable upscaling has been laid. Further market development, integration and international cooperation are crucial in the coming years.


REGMEDXB
PILOT FACTORY
ICAT
NecstGen
ReGEN Biomedical
n Services
Facilities
velopment
anufacturing
Automation
REGMEDXB
PILOT FACTORY

Organisation and communication

Governance
During 2024, the Supervisory Board met in four meetings with the Management team of RegMed XB. The main topics of discussion were the research activities, valorization, the Pilot Factory, the collaboration with Flanders and the roadmap for RegMed XB.

The Scientific Advisory Board met three times in 2024. The Moonshots were evaluated based on the scientific progress, ISAB reports, health foundations input and discussions with the Moonshot Leaders. As a result of these discussions, Milestone zero plans were adapted for 2024.

Support Office
The Office supports management and Moonshot leaders and coordinates interim and annual reporting. In 2024, personnel changes took place. Three members of the team left (Project Manager, Personal Assistant and Impact Officer) and four new employees joined RegMed XB (two Personal Assistants, a Project Management Lead and a Communications Manager). The additional PA function and the Communications Manager were replacements for freelancers.

International cooperation
International cooperation is of growing importance for the RegMed XB ambition. RegMed XB, where the XB stands for crossing borders, requires focused collaboration with world-leading institutes in regenerative medicine. The cooperation with Flanders gained further traction as the Office provided substantial support for the Flemish organisation. Also, the Flemish organisation hired additional personnel (1 FTE) for project management and general tasks. In the course of 2024, the Chair of RegMed XB Flanders joined the management team and strategic meetings. In future, the aim is to have one integrated Office supporting the Dutch and Flemish organisations.

In 2024 the Flemish government has recognized the importance of this cross-border collaboration awarding a further €15 million to RegMed XB Flanders, spread over a 5 year period, starting with a first €2,88 million in 2024.

In addition to its strong collaboration with Flanders, RegMed XB maintains close ties with key innovation hubs in regenerative medicine. These connections have been further strengthened through innovation missions to Switzerland, the UK, Germany, Sweden, and Japan. In Japan, a MoU was signed with Naganoshima Qross for fostering further collaboration. As a result of these activities, the Netherlands Innovation Network (“Innovatie Attachés”) of the Ministry of Economic Affairs has shown increased interest, leading to deeper relationships with Sweden and Japan. Further visits were planned for 2025, with scheduled trips to the US, France, Sweden, and Japan.

Communication and publications
Communication is of crucial importance within the institute and community building is key in a patient-oriented research organisation. In June 2024, the second Annual Conference was held in Maastricht, the main activity of the year. The Conference was open for participation from outside the RegMed XB community, leading to new participants from both the academic and industrial world. Several companies from outside the Netherlands showed interest as well. The Conference was well received by the participants and several important stakeholders took a role in the program, such as the Provincial Deputy for Government, Education and Labour market. Representatives of the Dutch government and Flanders participated as well. Feedback was positive and the meeting was well attended (> 200 participants).

RegMed XB pays much attention to external and internal communication. Especially communication via the social media platform LinkedIn became much more prominent. At the end of the year, RegMed XB published the Highlights 2024, providing an overall impression of the activities of RegMed XB.

Financial results

Investment and collaboration of partners can fulfil RegMed XB's role within the regenerative medicine ecosystem. The collective commitment is essential for the success and impact of the initiatives.

Last year, we received funding for projects and the operational costs of our office. Project funding primarily came from Health~Holland, various health foundations, contributions from academic partners, companies, and subsidies for the TTT program and the RegMed XB Pilot Factory.

BALANCE SHEET (€ x 1)	2024	2023
ASSETS		
Tangible fixed assets	53.617	7.672
Current assets	1.196.614	1.631.885
Cash and banks	1.618.937	1.911.419
Total	**2.869.168**	**3.550.975**
EQUITY AND LIABILITIES		
Current liabilities	2.869.168	3.550.975
Total	**2.869.168**	**3.550.975**

Project Revenues 2024 vs 2023



Project Expenses 2024 vs 2023



Revenues Office RegMed XB 2024 vs 2023



Expenses Office RegMed XB 2024 vs 2023



Outlook 2025

The focus of RegMed XB in 2025 will be on:

1. Further developing and applying for funding for the "Translatiemotor"
2. Secure research funding (Pillar 1) from Health~Holland as one of the strategic partners
3. Obtaining a new TTT-subsidy (Pillar 2-4)
4. Continuing the development of the RegMed XB's Pilot Factory (Pillar 5)
5. Further strengthening cooperation with Flanders
6. Building strategic partnerships, nationally and internationally

Roadmap RegMed XB
In 2024, RegMed XB developed a strategic plan for the future -the "Translatiemotor"- which was used for a National Growth Fund (NGF) application. Although the NGF no longer exists, all applications that were prepared for submission were compiled into the Bidbook by the Dutch Topsectors. This Bidbook was presented to the Minister of Economic Affairs, emphasizing that innovation is crucial for the Netherlands and that outstanding plans require funding. Discussions are ongoing regarding how best to invest in these initiatives. RegMed XB has been selected by the Topsectors as one of two examples to be pitched to public and private investors. This will take place over the course of 2024, creating new opportunities for the future.

Strategic pillar 1 - Research-Excellence
RegMed XB's program management in support of research-excellence has continued to mature, with activities within the Moonshots increasingly focusing on translation and building consensus on clear Roadmaps for both the short and long term.

For the **Diabetes Moonshot**, significant progress has been made in manufacturing stem cell-derived functional beta cells and developing a delivery device for these cells. A first clinical trial to assess the safety and tolerability of the device is now planned for 2026.

For the **Osteoarthritis Moonshot**, Roadmap discussions have been initiated, and overall, a clear path forward has been established for developing a living osteochondral implant for large and deep osteochondral defects. However, uncertainty regarding future funding remains, although financing in Flanders has been secured until 2026.
For the **Cardiovascular Moonshot**, the focus has shifted to ex vivo perfusion technology, which allows for longer-term survival (8–24 hours) and functional assessment of a heart ex vivo, transforming heart (donor heart) transplantation from an emergency procedure to an elective one. Additionally, the ex vivo model will be utilized to explore the efficiency of gene transfer.

The **Kidney Moonshot** continues preclinical studies on the production of stem cell-derived tubuloids, including in-depth functional characterization and scaling. Tubuloids will be explored as part of an organ-on-a-chip model, along with vascularization, in collaboration with Mimetas using the Organoplate platform. A long-term Roadmap is currently under discussion.

The **Eye Moonshot** aims to develop a corneal transplant for patients with keratitis bullosa, leveraging research expertise from both the Netherlands and Flanders. The Moonshot goal is to create a combination product featuring iPS-derived endothelial corneal cells seeded onto an unfoldable membrane, with timelines anticipating a first-in-human trial in 2029.

Finally, further integration with RegMed XB Flanders is planned to:
- Strengthen focus on critical areas requiring attention (e.g., regulatory affairs, large animal models, manufacturing platforms, business development).
- Better integrate the talent pool within the organization.
- Develop future leaders through targeted talent initiatives.



Strategic pillar 2, 3 and 4 – Business development & acceleration, Public-Private Entrepreneurship and Seed Capital
The focus of 2025 will be on continuing to build the valorization structure and associated activities. RegMed XB and DCVA applied for a new TTT-subsidy program, allowing for continuation of the former program. At the same time, collaboration with other NGF programs like Biotech Booster and Oncode Accelerator will be intensified, based on the collaboration agreement signed in October 2024. Other NGF programs are also interested to join this collaboration agreement.
Public-private entrepreneurship is supported not only by the SRGO subsidy but also by activities within the Moonshots. Growing interest from companies in joining RegMed XB is evident, as reflected in their increasing engagement. This is further underscored by their desire to be actively present at the 2025 Annual Conference, where for the first time several companies have requested the opportunity to host a booth.

Strategic pillar 5 – Infrastructure Pilot Factory
The RegMed XB's Pilot Factory will continue to expand as its final infrastructure is completed, and business activities are developed. Efforts must be intensified and broadened within the individual pilot lines, while RegMed XB plays a pivotal role in shaping the Pilot Factory as a whole. A great example of this progress was the presence of the RegMed XB's Pilot Factory booth at the recent TERMIS conference in Freiburg, May 2025.

Key focus areas include:
- Enhancing cooperation and coordination among pilot lines.
- Advancing the development and marketing of joint national and international business propositions.
- Strengthening business development activities to drive growth.
- Integrating the Pilot Factory within the broader RegMed XB ecosystem, ensuring alignment with its other pillars.
- Monitoring, evaluating, and reporting on both joint and individual progress through effective coordination.
- Continuing infrastructure development and reinforcing organizational strength.

International collaboration
RegMed XB will continue to explore international collaboration opportunities. With support from the Innovation Counsels of Embassies abroad, as well as the NFIA and RVO, strategic visits will be planned to foster global partnerships. Given RegMed XB's relatively small Office, careful decisions must be made regarding priorities.

The collaboration with Flanders will undoubtedly be strengthened further. Additionally, ties with Japan will be deepened, and this year RegMed XB will formalize its partnership with Inserm, the French health research institute, through the signing of a Memorandum of Understanding (MoU).

RegMed XB will also seek further collaboration with other European countries, including Germany, and potentially Italy and Spain, to build critical mass in the field of regenerative medicine. These efforts will support advocacy for innovation funding from the European Commission.

Community building
A key pillar of RegMed XB is its commitment to transcending disciplinary, academic, industrial, and regional boundaries. The major event of 2025 will be the third RegMed XB Annual Conference, held in Leuven, Belgium. For the third time, the Conference will welcome participants from outside the RegMed XB's consortium.

This Annual Conference will not only highlight research but also emphasize valorization and the Pilot Factory.
Its extensive program encompasses all aspects of the RegMed XB platform, fostering interdisciplinary interaction - an essential element for achieving RegMed XB's overarching mission: delivering regenerative medicine solutions to patients at affordable prices.

Thanks to all Partners

Academic partners

Ghent University

KU Leuven

Leids Universitair Medisch Centrum

Maastricht University

Maastricht UMC+

TU/e Eindhoven University of Technology

University of Antwerp

UMC Utrecht

Utrecht University

VUB Vrije Universiteit Brussel

VIB

Health Foundations

Diabetes Fonds

don We just care for cure

Hartstichting

Nierstichting Je nieren zijn je leven.

Oogfonds

ReumaNederland

Pilot lines

ICAT Innovation Center for Advanced Therapies

Leids Universitair Medisch Centrum

NecstGen

ReGEN Biomedical

SBMC Smart BioMaterials Consortium

Industrial and valorisation partners

Access2bone
AXION BIOSYSTEMS
CiMaas A better cure for cancer
Coagulation Profile
Dutch CardioVascular Alliance
ETB-BISLIFE
eurobiogendx
FUJIFILM VISUALSONICS
HCM Medical
interflow
Kuros Biosciences
MIMETAS
Ncardia Stem cell experts
NTrans TECHNOLOGIES
QUALITY ASSISTANCE Contract Research Organisation
scannexus
SCINUS CELL EXPANSION
SINGLE CELL DISCOVERIES
Starfish INNOVATIONS
STENTIT
SupraPolix
U-CyTech biosciences
veldlaser
XELTIS
300MICRONS Flexible 3D Cell Culture Solutions

Governmental partners

NL Health~Holland
Flanders State of the Art
provincie limburg
Provincie Noord-Brabant
PROVINCIE :: UTRECHT
provincie Zuid-Holland
Ministerie van Economische Zaken
Ministerie van Volksgezondheid, Welzijn en Sport
Ministerie van Onderwijs, Cultuur en Wetenschap
Nationaal Groeifonds

Together we make the impossible possible

REGMEDXB
FROM CARE TO CURE